HEMOPHILIA FEDERATION OF AMERICA for HEMOPHILIA FEDERATION AMERICA
What was lobbied
One issue area, each in the filer's own words, with who lobbied on it and where.
Health Issues HCR
HR 1600, The Patients' Access to Treatment Act - a bill that states that insurance companies cannot charge more for the drugs that they place on specialty tiers than they charge for the drugs on their non-preferred brand tier, designed to protect patients with chronic and expensive conditions from increase percentage cost sharing by insurers; HR 3742 - The Access to Marketplace Insurance Act - a bill that states that adds nonprofits to a list of entities that insurance companies on the exchange must accept premium assistance from, designed to allow patients with chronic and expensive disorders to afford quality insurance; biosimilar implementation - concerned that new rules regarding biosimilar approval offer proper patient protections.
| Lobbyist | Covered position, as disclosed |
|---|---|
| KATIE VERB | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.